Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVAC-1 in High-risk CLL
NCT03265717Phase 2Terminated
- Sponsor
- Invectys
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of INVAC-1 in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Invectys. Primary endpoint: Minimal Residual Disease (MRD) eradication rate in the bone marrow at 6 months. Started Jul 2018; status: terminated.
02
Drugs
INVAC-1
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03265717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03265717.